Why Are mpMRIs Negative in Men with Clinically Significant Prostate Cancer?
Why clinically significant prostate cancer may not appear on multiparametric MRI.
Read More
Select Page
Alberto Vargas, MD, is Vice Chair of Oncology Imaging and Strategy, and a Professor within the Department of Radiology at New York University in New York City. Dr. Vargas specializes in oncological and molecular imaging. His clinical and research interests focus on the use of advanced-imaging modalities, including diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging and novel positron emission tomography tracers for the non-invasive diagnosis, staging, treatment response assessment, and follow-up of patients with cancer. Dr. Vargas is especially interested in imaging patients with cancers involving the urinary system and the female reproductive organs.
Dr. Vargas earned his medical degree from Central University of Venezuela in Caracas. He completed a residency in Diagnostic Radiology at Cambridge University in the United Kingdom. Dr. Vargas then completed a fellowship in Oncologic Imaging and a residency in Nuclear Medicine at Memorial Sloan Kettering Cancer Center in New York, New York.
Alberto Vargas, MD | Apr 2026
Why clinically significant prostate cancer may not appear on multiparametric MRI.
Read MoreAlberto Vargas, MD | Apr 2026
MRI plays a central role in focal therapy planning, but post-treatment interpretation remains challenging and poorly standardized.
Read MoreAlberto Vargas, MD | Jan 2026
Alberto Vargas, MD, discusses the clinical and prognostic implications of prostate cancer visibility on MRI. He explains how technical factors, tumor biology, and radiologist expertise influence detection and outlines how visibility informs prognosis and patient management.
Read MoreAlberto Vargas, MD | Apr 2025
Alberto Vargas, MD, examines the integration of AI into prostate MRI, focusing on its current state, challenges, and future implications.
Read MoreAlberto Vargas, MD | Dec 2024
Alberto Vargas, MD, offers an in-depth exploration of theranostics in oncology, focusing on prostate cancer.
Read More